Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hikma Pharmaceuticals PLC

www.hikma.com

Latest From Hikma Pharmaceuticals PLC

US Generics Market Continues To Seek Stability

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

Market Intelligence Generic Drugs

Hikma Eyes Top End Of Forecasts

Hikma has set out updated full-year forecasts in a trading update that indicates its 2019 generics sales will hit the “top end” of its $690m-$720m expectations.

Sales & Earnings Commercial

Orion Defends Position In Declining Finnish Market

Amid declining sales of drugs covered by reference prices in Finland, local leader Orion says it has been able to slightly strengthen its market position.

Finland Generic Drugs

US Supreme Court Refuses ‘Blocking-Patent’ Review

Acorda has been denied its request for the US Supreme Court to review a ruling that revolved around the ‘blocking-patent’ doctrine, which has led to invalidity rulings on patents protecting several major brands.

Intellectual Property Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Hikma Pharmaceuticals PLC
  • Senior Management
  • Said Darwazah, Chmn. & CEO
    Khalid Nabilsi, CFO
    Bassam Kanaan, Chief Strategy & Corp. Dev. Officer
  • Contact Info
  • Hikma Pharmaceuticals PLC
    Phone: (44) 20 7399 2760
    1 New Burlington Pl.
    London, W1S 2HR
    UK
UsernamePublicRestriction

Register